Literature DB >> 2819714

Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells.

J Posada1, P Vichi, T R Tritton.   

Abstract

Adriamycin has a wide variety of biological actions on susceptible cells, several of which may be integrally involved in cytotoxicity. In this paper, we present evidence that one of the alterations in cell function that occurs in the presence of Adriamycin is an elevation in the production of diacylglycerol. The effect is rapid, reaches a peak within 10 min of exposure of Sarcoma 180 cells to Adriamycin, and can thus be classified among the earliest alterations that occur in cells damaged by Adriamycin. Concomitant with the rise in diacylglycerol is an increase in cytosolic protein kinase C activity. Although Adriamycin does not appear to modulate the activity of this enzyme by direct binding, drug-exposed Sarcoma 180 cells have a 56% increase in intrinsic cytosolic protein kinase C (PKC) activity, with no change in the activity of the membrane form. Experiments with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate suggest that the PKC effect is linked to Adriamycin action, since activation of the enzyme by short 12-O-tetradecanoylphorbol-13-acetate exposure enhances Adriamycin's cytotoxicity as well as its ability to provoke DNA damage (measured by alkaline elution). Likewise, down-regulation of PKC by extended 12-O-tetradecanoylphorbol-13-acetate exposure partially protects the cells from Adriamycin-induced cytotoxicity as well as from DNA damage. Thus, the ability of cells to be injured by Adriamycin appears to be correlated with the activity of PKC. Multidrug-resistant subline Sarcoma 180A10 cells have the same total quantity of membrane-recruitable PKC as the sensitive parent Sarcoma 180 cells, as determined by [3H]phorbol-12,13-dibutyrate binding. However, the resistant cells have a significantly higher intrinsic PKC activity and an altered ability to translocate the enzyme to the cell surface. Taken together, the results raise the possibility that cell signaling mechanisms, particularly those involving protein kinase C, may play an important role in mediating the biological action of the anticancer drug Adriamycin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2819714

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Dexniguldipine hydrochloride, a protein-kinase-C-specific inhibitor, affects the cell cycle, differentiation, P-glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells.

Authors:  K K Patterson; B S Beckman; D M Klotz; C M Mallia; J R Jeter
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Protein kinases and multidrug resistance.

Authors:  M G Rumsby; L Drew; J R Warr
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance.

Authors:  Y P Hu; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  Protein kinase C-independent correlation between P-glycoprotein expression and volume sensitivity of Cl- channel.

Authors:  A Miwa; K Ueda; Y Okada
Journal:  J Membr Biol       Date:  1997-05-01       Impact factor: 1.843

Review 5.  Effects of phosphorylation of P-glycoprotein on multidrug resistance.

Authors:  U A Germann; T C Chambers; S V Ambudkar; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

6.  Role of protein kinase C in adriamycin-induced erythroid differentiation of K562 cells.

Authors:  R Hoffman; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Evaluation of 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)- hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro.

Authors:  E C Sha; M C Sha; S H Kaufmann
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 8.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 9.  Linker Domains: Why ABC Transporters 'Live in Fragments no Longer'.

Authors:  Robert C Ford; Dominic Marshall-Sabey; John Schuetz
Journal:  Trends Biochem Sci       Date:  2019-12-12       Impact factor: 13.807

Review 10.  Role of protein kinases in antitumor drug resistance.

Authors:  H Grunicke; J Hofmann; I Utz; F Uberall
Journal:  Ann Hematol       Date:  1994       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.